Non-alcoholic fatty liver disease and risk of cardiovascular disease

被引:171
|
作者
Lonardo, Amedeo [1 ,2 ,3 ]
Sookoian, Silvia [4 ]
Pirola, Carlos J. [5 ]
Targher, Giovanni
机构
[1] Azienda USL, NOCSAE, Dept Biomed Metab & Neural Sci, Outpatient Liver Clin, Modena, Italy
[2] Azienda USL, NOCSAE, Dept Biomed Metab & Neural Sci, Div Internal Med, Modena, Italy
[3] Univ Modena & Reggio Emilia, Modena, Italy
[4] Univ Buenos Aires, Nat Sci & Tech Res Council CONICET, Inst Med Res A Lanari IDIM, Dept Clin & Mol Hepatol, Buenos Aires, DF, Argentina
[5] Univ Buenos Aires, Nat Sci & Tech Res Council CONICET, Inst Med Res A Lanari IDIM, Dept Mol Genet & Biol Complex Dis, Buenos Aires, DF, Argentina
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2016年 / 65卷 / 08期
关键词
NAFLD; CVD; Cardiovascular risk; GAMMA-GLUTAMYL-TRANSFERASE; CORONARY-HEART-DISEASE; SUPERFAMILY MEMBER 2; TERM-FOLLOW-UP; HEPATIC STEATOSIS; PHYSICAL-ACTIVITY; INSULIN-RESISTANCE; DIABETES-MELLITUS; CONFERS SUSCEPTIBILITY; ATRIAL-FIBRILLATION;
D O I
10.1016/j.metabol.2015.09.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. During the past decade, it has also become increasingly evident that NAFLD is a multisystem disease that affects many extra-hepatic organ systems, including the heart and the vascular system. In this updated clinical review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong association of NAFLD with cardiovascular diseases (CVDs) and other functional and structural myocardial abnormalities. We also discuss some recently published data that correlate NAFLD due to specific genetic polymorphisms with the risk of CVDs. Finally, we briefly examine the assessment tools for estimating the global CVD risk in patients with NAFLD as well as the conventional and the more innovative pharmacological approaches for the treatment of CVD risk in this group of patients. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:1136 / 1150
页数:15
相关论文
共 50 条
  • [31] Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
    Targher, Giovanni
    Byrne, Christopher D.
    Lonardo, Amedeo
    Zoppini, Giacomo
    Barbui, Corrado
    JOURNAL OF HEPATOLOGY, 2016, 65 (03) : 589 - 600
  • [32] Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population
    Pennisi, Grazia
    Di Marco, Vito
    Buscemi, Carola
    Mazzola, Giovanni
    Randazzo, Cristiana
    Spatola, Federica
    Craxi, Antonio
    Buscemi, Silvio
    Petta, Salvatore
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (09) : 2389 - 2396
  • [33] Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting
    Linero, Paula Luque
    Castilla-Guerra, Luis
    EUROPEAN CARDIOLOGY REVIEW, 2024, 19
  • [34] Non-alcoholic fatty liver disease
    Powell, Elizabeth E.
    Wong, Vincent Wai-Sun
    Rinella, Mary
    LANCET, 2021, 397 (10290) : 2212 - 2224
  • [35] Early life programming and the risk of non-alcoholic fatty liver disease
    Lynch, C.
    Chan, C. S.
    Drake, A. J.
    JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE, 2017, 8 (03) : 263 - 272
  • [36] Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease
    Janssen, Arne
    Grobbee, Diederick E.
    Dendale, Paul
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (10) : 1059 - 1063
  • [37] Non-alcoholic fatty liver disease and risk of type 2 diabetes
    Lallukka, S.
    Yki-Jarvinen, H.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 30 (03) : 385 - 395
  • [38] Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
    Martin, Anna
    Lang, Sonja
    Goeser, Tobias
    Demir, Muenevver
    Steffen, Hans-Michael
    Kasper, Philipp
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (07) : 533 - 546
  • [39] Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints
    Buckley, Adam J.
    Thomas, E. Louise
    Lessan, Nader
    Trovato, Francesca M.
    Trovato, Guglielmo M.
    Taylor-Robinson, Simon D.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 144 : 144 - 152
  • [40] Current therapeutic strategies in non-alcoholic fatty liver disease
    Dowman, J. K.
    Armstrong, M. J.
    Tomlinson, J. W.
    Newsome, P. N.
    DIABETES OBESITY & METABOLISM, 2011, 13 (08) : 692 - 702